A major federal appellate decision may significantly change how the Drug Enforcement Administration (DEA) prosecutes pharmacies for controlled-substance violations.
In Neumann’s Pharmacy, LLC v. DEA, the U.S. Court of Appeals for the Fifth Circuit rejected the DEA’s long-standing interpretation of two key Controlled Substances Act regulations governing pharmacists:
- 21 C.F.R. §1306.04(a) — the pharmacist’s “corresponding responsibility”
- 21 C.F.R. §1306.06 — dispensing controlled substances within the “usual course of professional practice”
For years, the DEA has relied on these regulations to revoke pharmacy registrations and pursue enforcement actions based on alleged “red flags” of diversion.
The Fifth Circuit’s decision substantially narrows that authority.
For pharmacies, physicians, and healthcare businesses operating in the controlled-substance space, this ruling is one of the most important DEA cases in years.
The Case: DEA Revokes a Pharmacy Registration
The dispute arose after the DEA revoked the registration of Neumann’s Pharmacy, a Louisiana pharmacy accused of dispensing controlled substances despite alleged diversion “red flags.”
The DEA alleged the pharmacy improperly filled prescriptions involving:
- opioid and benzodiazepine combinations
- butalbital and benzodiazepine combinations
- “therapeutic duplication” (multiple formulations of the same drug)
- patients paying cash for controlled substances while using insurance for others
- prescriptions written for family members allegedly violating state law
DEA relied heavily on expert testimony regarding pharmacy standards of care and concluded the pharmacy had violated the Controlled Substances Act.
The agency revoked the pharmacy’s registration.
The pharmacy appealed to the Fifth Circuit.
The Fifth Circuit Rejects DEA’s Interpretation
The Fifth Circuit ruled that the DEA misinterpreted its own regulations and sent the case back to the agency.
The court’s opinion sharply criticized the DEA’s enforcement framework, explaining that the agency had expanded pharmacist liability beyond what the regulations actually allow.
The ruling focused on two central regulatory provisions.
1. DEA’s “Corresponding Responsibility” Standard Was Too Broad
The DEA has historically taken the position that pharmacists violate the Controlled Substances Act if they fill prescriptions when they “knew or should have known” the prescription lacked a legitimate medical purpose.
The Fifth Circuit rejected that interpretation.
According to the court, the corresponding responsibility regulation only creates liability if three elements are proven:
- The pharmacist filled a prescription
- The prescription was invalid when issued
- The pharmacist knowingly filled the invalid prescription
This interpretation dramatically narrows the scope of liability.
Actual Knowledge Is Now Required
Under the Fifth Circuit’s reading of the regulation, a pharmacist violates the law only if the pharmacist actually knew the prescription was invalid.
The court rejected the DEA’s “should have known” standard.
The agency attempted to argue that its standard reflected the doctrine of willful blindness, but the court disagreed.
True willful blindness requires:
- a subjective belief that wrongdoing is likely, and
- deliberate efforts to avoid confirming that suspicion
DEA’s interpretation instead imposed what the court described as an objective negligence standard, which the regulation does not support.
For enforcement purposes, that distinction is critical.
2. Violating a Pharmacy Standard of Care Is Not a Federal Crime
The Fifth Circuit also rejected the DEA’s interpretation of the phrase “usual course of professional practice.”
The DEA had argued that pharmacists violate federal law whenever their conduct falls below state-law pharmacy standards of care.
The court held that this interpretation was legally incorrect.
Historically, the phrase refers to bona fide medical practice, not ordinary malpractice or negligence.
The court warned that the DEA’s interpretation would effectively:
“convert every act of negligence under state law into a federal felony.”
In other words, bad pharmacy practice is not the same thing as drug trafficking.
To establish a federal violation, the government must show conduct outside legitimate pharmacy operations.
What This Means for DEA Investigations
The ruling significantly raises the burden the DEA must meet when bringing enforcement actions against pharmacies.
Under the Fifth Circuit’s interpretation, the government must prove:
- the prescription was actually invalid when written, and
- the pharmacist knew it was invalid
That is a much more demanding standard than the DEA’s previous enforcement theory.
It also means that expert testimony about pharmacy “red flags” or alleged negligence may not be enough.
Instead, the government must show that the pharmacy’s conduct crossed the line from legitimate practice into illegal drug distribution.
A Circuit Split May Be Emerging
The Fifth Circuit’s decision conflicts with earlier rulings from other federal courts.
For example, the Sixth Circuit previously allowed enforcement actions under the DEA’s broader “knew or should have known” standard.
That disagreement between circuits increases the likelihood that the issue may eventually be resolved by the U.S. Supreme Court.
Until then, the Fifth Circuit’s decision will likely influence how DEA administrative cases and pharmacy revocation proceedings are litigated.
Practical Takeaways for Pharmacies and Healthcare Providers
The ruling does not eliminate DEA enforcement risk. But it does clarify several important legal principles.
1.DEA enforcement theories may face greater judicial scrutiny.
Courts appear increasingly willing to examine whether agencies are expanding regulatory language beyond what the law actually says.
2.Actual knowledge now matters.
At least within the Fifth Circuit, pharmacist liability depends on whether the pharmacist actually knew a prescription was invalid.
3.Negligence alone is not enough.
Violating professional standards of care does not automatically create federal criminal liability.
4.“Red flags” alone may not justify DEA revocation.
The government must demonstrate conduct outside legitimate pharmacy practice.
Why This Case Matters
For nearly two decades, DEA enforcement actions against pharmacies have relied heavily on the “red flags” theory of diversion.
The Fifth Circuit’s decision calls that approach into question.
The ruling also reflects a broader trend in federal courts: increasing skepticism toward agencies expanding regulatory power through interpretation rather than rulemaking.
For pharmacies and healthcare providers navigating controlled-substance compliance, understanding these developments is critical.
If your pharmacy or medical practice is facing a DEA investigation, audit, or registration proceeding, understanding how courts interpret these regulations can make the difference between regulatory compliance and federal enforcement exposure.